Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tiziana Life Sciences PLC

1.57
+0.09006.08%
Post-market: 1.620.0500+3.18%18:46 EDT
Volume:377.22K
Turnover:589.16K
Market Cap:163.28M
PE:-11.77
High:1.60
Open:1.56
Low:1.50
Close:1.48
Loading ...

Tiziana Life Sciences announces discovery of new immune biomarkers

TIPRANKS
·
23 Jan

Tiziana Life Sciences Ltd - Gene Expression Changes Detected Three Months After Foralumab Dosing

THOMSON REUTERS
·
23 Jan

Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated With Nasal Foralumab

THOMSON REUTERS
·
23 Jan

3 Penny Stocks In US With Market Caps Below $300M

Simply Wall St.
·
13 Jan

BRIEF-Tiziana Announces Reduction Of Side Effects Commonly Seen With Discontinuation Of GLP-1 Agonists With Nasal Anti-CD3

Reuters
·
10 Jan

Tiziana Life Sciences announces findings on nasal anti-CD3 monoclonal antibody

TIPRANKS
·
10 Jan

Tiziana Life Sciences: Reduction of Side Effects Seen With Discontinuation of Glp-1 Agonists With Nasal Anti-Cd3

THOMSON REUTERS
·
10 Jan

Tiziana Life Sciences Ltd - FDA Allows Additional 20 Patients in Foralumab Expanded Access Program

THOMSON REUTERS
·
10 Jan

Tiziana Life Sciences Ltd - Glp-1 Drugs Face Long Term Tolerability Issues

THOMSON REUTERS
·
10 Jan

Tiziana Announces Reduction of Side Effects Commonly Seen With Discontinuation of Glp-1 Agonists With Nasal Anti-Cd3

THOMSON REUTERS
·
10 Jan

Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease

THOMSON REUTERS
·
08 Jan

Tiziana Life Sciences announces first patient dosed with intranasal foralumab

TIPRANKS
·
17 Dec 2024

Tiziana Life Sciences Announces First Patient With Moderate Alzheimer’s Disease Dosed With Intranasal Foralumab

THOMSON REUTERS
·
17 Dec 2024

3 US Penny Stocks With Market Caps Under $200M To Consider

Simply Wall St.
·
05 Dec 2024

Tiziana Life Sciences Expands MS Clinical Trial Network

TIPRANKS
·
04 Dec 2024

Tiziana Life Sciences expands Phase 2 trial for non-active SPMS

TIPRANKS
·
04 Dec 2024